Welcome to our dedicated page for Kenvue SEC filings (Ticker: KVUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kenvue Inc. filings document the public-company disclosures of a pure-play consumer health issuer with brands including Tylenol, Listerine, Johnson’s, Aveeno, Neutrogena and BAND-AID Brand. Its SEC record includes material-event reports, proxy and governance disclosures, shareholder voting matters, capital-structure information, operating and financial results, and consumer-health regulatory topics.
The company’s filings also cover executive officer appointments and compensatory arrangements, material definitive agreements, risk-factor disclosures and common-stock matters. Proxy materials and Form 8-K reports provide formal records of board governance, security-holder votes and other events affecting Kenvue’s corporate structure and reporting obligations.
Kenvue Inc. executive Lawson Carlton, Group President EMEA & LA, exercised restricted stock units that converted into 7736.1700 shares of common stock on 2026-03-05. The reporting person retained all shares acquired upon vesting and paid related tax withholdings in cash.
The restricted stock unit award corresponds 1-for-1 with Kenvue common stock and vests in three equal installments on 03/05/2025, 03/05/2026, and 03/05/2027, subject to continued service. Following the transaction, direct common stock holdings totaled 105257.2000 shares, including shares acquired in dividend reinvestment transactions.
Kenvue Inc. Chief People Officer Luani Alvarado reported equity award activity involving restricted stock units and common shares. On the same date, 4,289.080 restricted stock units were exercised or converted into 4,289.080 shares of common stock at a stated price of $0.0000 per share.
Following these conversions, directly held common stock increased to 61,365.220 shares before a separate tax-related transaction. In a related move, 2,094 common shares, valued at $18.25 per share, were withheld to cover tax obligations upon vesting, leaving 59,271.220 common shares directly owned. Restricted stock units outstanding after these events totaled 4,290.220 units, corresponding one-for-one with common stock and vesting in three equal installments through 2027.
Kenvue Inc. Chief Operations Officer Meredith Stevens reported equity award activity involving restricted stock units and common stock. On March 5, 2026, she exercised or converted 6,178.21 restricted stock units, which correspond 1-for-1 to Kenvue common stock, into 6,178.21 shares of common stock.
In a related tax-withholding transaction, 1,677 common shares were withheld at $18.25 per share to cover taxes due upon vesting of the restricted stock units. After these transactions, she directly held 90,547.39 common shares and 6,177.23 restricted stock units, with the award scheduled to vest in three equal installments on March 5, 2025, 2026, and 2027, subject to continued service.
Kenvue Inc. VP & Chief Accounting Officer Heather Howlett reported equity award activity involving restricted stock units and common stock. On 03/05/2026, 2,722.87 restricted stock units, which correspond 1-for-1 with Kenvue common stock, were converted into 2,722.87 common shares. On the same date, 933 common shares at $18.25 per share were withheld to cover taxes due at vesting, leaving her with 32,988.37 common shares held directly. Following the transaction, 2,721.89 restricted stock units remained outstanding, and her holdings also include shares acquired through dividend reinvestment.
Kenvue Inc. reported that its General Counsel, Matthew Orlando, received a grant of 122,286 Restricted Stock Units (RSUs) on March 2, 2026. These RSUs were acquired at a price of $0.00 per unit as a compensation award and now represent his total reported RSU holdings.
The units correspond on a 1-for-1 basis with Kenvue common stock. The award is scheduled to vest in three equal installments on March 2, 2027, March 2, 2028, and March 2, 2029, provided he continues in service through each vesting date.
Kenvue Inc. reported that Chief Tech & Data Officer Michael Wondrasch acquired a grant of 79,407 restricted stock units (RSUs), each corresponding 1-for-1 to Kenvue common stock. The award vests in three equal installments on March 2, 2027, March 2, 2028, and March 2, 2029, contingent on his continued service with the company through each vesting date.
Kenvue Inc. reported that Group President LATAM Leonardo Curado Gomes de Lemos acquired 13,234 restricted stock units as an equity award. These units correspond 1-for-1 with Kenvue common stock. The award vests in three equal installments on March 2 of 2027, 2028, and 2029, contingent on continued service.
Dasgupta Anindya reported acquisition or exercise transactions in this Form 4 filing.
Kenvue Inc. reported that Group President APAC Anindya Dasgupta received a grant of 98,994 Restricted Stock Units on 03/02/2026. These RSUs correspond 1-for-1 with Kenvue common stock and were awarded at no purchase price. The award vests in three equal installments on 03/02/2027, 03/02/2028, and 03/02/2029, contingent on his continued service through each vesting date.
Kenvue Inc. vice president and chief accounting officer Heather Howlett reported several equity-compensation transactions. On March 2, 2026, she received a grant of 22,233 Restricted Stock Units that correspond 1-for-1 with Kenvue common stock and vest in three equal installments on March 2 of 2027, 2028, and 2029, subject to continued service. On March 3, 2026, 1,534.48 Restricted Stock Units were converted into the same number of common shares, and 526 shares of common stock were withheld at $18.15 per share to cover taxes upon vesting. After these transactions, she directly owned 31,198.5 shares of common stock.
Kenvue Inc. reported that Group President EMEA & LA Lawson Carlton acquired a grant of 93,488 restricted stock units. These RSUs carry no purchase price and correspond on a one-for-one basis with Kenvue common stock. The award vests in three equal installments on March 2, 2027, March 2, 2028, and March 2, 2029, conditioned on Carlton’s continued service through each vesting date. This filing reflects equity-based compensation rather than an open-market share purchase or sale.